-
1
-
-
57849138262
-
Children’s Oncology Group. Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children’s Oncology Group study
-
Nguyen K, Devidas M, Cheng SC, et al; Children’s Oncology Group. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study. Leukemia. 2008;22(12):2142-2150.
-
(2008)
Leukemia
, vol.22
, Issue.12
, pp. 2142-2150
-
-
Nguyen, K.1
Devidas, M.2
Cheng, S.C.3
-
2
-
-
47049093795
-
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children’s Oncology Group study
-
Borowitz MJ, Devidas M, Hunger SP, et al; Children’s Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008;111(12):5477-5485.
-
(2008)
Blood
, vol.111
, Issue.12
, pp. 5477-5485
-
-
Borowitz, M.J.1
Devidas, M.2
Hunger, S.P.3
-
5
-
-
85026829845
-
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
-
Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92(9):946-965.
-
(2017)
Am J Hematol
, vol.92
, Issue.9
, pp. 946-965
-
-
Hallek, M.1
-
6
-
-
34347378243
-
How I treat patients with diffuse large B-cell lymphoma
-
Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110(1):29-36.
-
(2007)
Blood
, vol.110
, Issue.1
, pp. 29-36
-
-
Armitage, J.O.1
-
7
-
-
84861122295
-
The future is now: Chimeric antigen receptors as new targeted therapies for childhood cancer
-
Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res. 2012;18(10):2780-2790.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.10
, pp. 2780-2790
-
-
Lee, D.W.1
Barrett, D.M.2
Mackall, C.3
Orentas, R.4
Grupp, S.A.5
-
8
-
-
84880951421
-
Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers
-
Orentas RJ, Yang JJ, Wen X, Wei JS, Mackall CL, Khan J. Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Front Oncol. 2012;2:194.
-
(2012)
Front Oncol
, vol.2
, pp. 194
-
-
Orentas, R.J.1
Yang, J.J.2
Wen, X.3
Wei, J.S.4
Mackall, C.L.5
Khan, J.6
-
9
-
-
84904097189
-
Current concepts in the diagnosis and management of cytokine release syndrome
-
Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-195.
-
(2014)
Blood
, vol.124
, Issue.2
, pp. 188-195
-
-
Lee, D.W.1
Gardner, R.2
Porter, D.L.3
-
10
-
-
85011955241
-
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
-
Teachey DT, Lacey SF, Shaw PA, et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016;6(6):664-679.
-
(2016)
Cancer Discov
, vol.6
, Issue.6
, pp. 664-679
-
-
Teachey, D.T.1
Lacey, S.F.2
Shaw, P.A.3
-
11
-
-
33748416499
-
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
-
Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018-1028.
-
(2006)
N Engl J Med
, vol.355
, Issue.10
, pp. 1018-1028
-
-
Suntharalingam, G.1
Perry, M.R.2
Ward, S.3
-
12
-
-
84988805188
-
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
-
355ra116
-
Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355): 355ra116.
-
(2016)
Sci Transl Med
, vol.8
, Issue.355
-
-
Turtle, C.J.1
Hanafi, L.A.2
Berger, C.3
-
13
-
-
84974555520
-
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
-
Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123-2138.
-
(2016)
J Clin Invest
, vol.126
, Issue.6
, pp. 2123-2138
-
-
Turtle, C.J.1
Hanafi, L.A.2
Berger, C.3
-
14
-
-
84923019006
-
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial
-
Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-528.
-
(2015)
Lancet
, vol.385
, Issue.9967
, pp. 517-528
-
-
Lee, D.W.1
Kochenderfer, J.N.2
Stetler-Stevenson, M.3
-
15
-
-
84908073316
-
Chimeric antigen receptor T cells for sustained remissions in leukemia
-
Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.
-
(2014)
N Engl J Med
, vol.371
, Issue.16
, pp. 1507-1517
-
-
Maude, S.L.1
Frey, N.2
Shaw, P.A.3
-
16
-
-
85040171486
-
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
-
Schuster SJ, Svoboda J, Chong EA, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017; 377(26):2545-2554.
-
(2017)
N Engl J Med
, vol.377
, Issue.26
, pp. 2545-2554
-
-
Schuster, S.J.1
Svoboda, J.2
Chong, E.A.3
-
17
-
-
85041377767
-
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
-
Park JH, Rivière I, Gonen M, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):449-459.
-
(2018)
N Engl J Med
, vol.378
, Issue.5
, pp. 449-459
-
-
Park, J.H.1
Rivière, I.2
Gonen, M.3
-
18
-
-
84923118622
-
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
-
Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-549.
-
(2015)
J Clin Oncol
, vol.33
, Issue.6
, pp. 540-549
-
-
Kochenderfer, J.N.1
Dudley, M.E.2
Kassim, S.H.3
-
19
-
-
84876325876
-
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
-
Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16): 1509-1518.
-
(2013)
N Engl J Med
, vol.368
, Issue.16
, pp. 1509-1518
-
-
Grupp, S.A.1
Kalos, M.2
Barrett, D.3
-
20
-
-
84876005284
-
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
-
177ra38
-
Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177): 177ra38.
-
(2013)
Sci Transl Med
, vol.5
, Issue.177
-
-
Brentjens, R.J.1
Davila, M.L.2
Riviere, I.3
-
24
-
-
85044163933
-
-
United States Food and Drug Administration Press Release. Accessed August 30, 2017
-
FDA approval brings first gene therapy to the United States. Available from: https://www.fda.gov/newsevents/newsroom/pressannounce-ments/ucm574058.htm. United States Food and Drug Administration Press Release. Accessed August 30, 2017.
-
FDA Approval Brings First Gene Therapy to the United States
-
-
-
25
-
-
12344312699
-
-
V4.03. 2010. National Institutes of Health, Bethesda, MD, Accessed March 21, 2018
-
US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). V4.03. 2010. National Institutes of Health, Bethesda, MD. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf. Accessed March 21, 2018.
-
Common Terminology Criteria for Adverse Events (CTCAE)
-
-
-
26
-
-
84896335556
-
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
-
224ra25
-
Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224): 224ra25.
-
(2014)
Sci Transl Med
, vol.6
, Issue.224
-
-
Davila, M.L.1
Riviere, I.2
Wang, X.3
-
27
-
-
85042858745
-
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
-
Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35.
-
(2018)
J Hematol Oncol
, vol.11
, Issue.1
, pp. 35
-
-
Porter, D.1
Frey, N.2
Wood, P.A.3
Weng, Y.4
Grupp, S.A.5
-
28
-
-
85038265543
-
Chimeric antigen receptor T-cell therapy assessment and management of toxicities
-
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62.
-
(2018)
Nat Rev Clin Oncol
, vol.15
, Issue.1
, pp. 47-62
-
-
Neelapu, S.S.1
Tummala, S.2
Kebriaei, P.3
-
29
-
-
12344312699
-
-
V5.0. 2018. National Institutes of Health, Bethesda, MD, Accessed on March 09, 2018
-
US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). V5.0. 2018. National Institutes of Health, Bethesda, MD. Available from: https://ctep.cancer.gov/pro-tocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference:8.5x11.pdf. Accessed on March 09, 2018.
-
Common Terminology Criteria for Adverse Events (CTCAE)
-
-
-
30
-
-
85060291519
-
ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
-
Epub, Dec 25
-
Lee DW, Santomasso BD, Locke FL, et al. ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. Epub 2018 Dec 25.
-
(2018)
Biol Blood Marrow Transplant
-
-
Lee, D.W.1
Santomasso, B.D.2
Locke, F.L.3
-
31
-
-
85037359093
-
Endothelial Activation and BloodBrain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
-
Gust J, Hay KA, Hanafi LA, et al. Endothelial Activation and BloodBrain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017;7(12): 1404-1419.
-
(2017)
Cancer Discov
, vol.7
, Issue.12
, pp. 1404-1419
-
-
Gust, J.1
Hay, K.A.2
Hanafi, L.A.3
-
32
-
-
85047813147
-
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
-
Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739-748.
-
(2018)
Nat Med
, vol.24
, Issue.6
, pp. 739-748
-
-
Norelli, M.1
Camisa, B.2
Barbiera, G.3
-
33
-
-
85047803079
-
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
-
Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731-738.
-
(2018)
Nat Med
, vol.24
, Issue.6
, pp. 731-738
-
-
Giavridis, T.1
Van Der Stegen, S.2
Eyquem, J.3
Hamieh, M.4
Piersigilli, A.5
Sadelain, M.6
-
34
-
-
85048303785
-
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates
-
Taraseviciute A, Tkachev V, Ponce R, et al. Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. Cancer Discov. 2018;8(6):750-763.
-
(2018)
Cancer Discov
, vol.8
, Issue.6
, pp. 750-763
-
-
Taraseviciute, A.1
Tkachev, V.2
Ponce, R.3
-
35
-
-
85046889779
-
The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: A systematic review
-
May 15
-
Jin Z, Xiang R, Qing K, et al. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review. Ann Hematol. Epub 2018 May 15.
-
(2018)
Ann Hematol. Epub
-
-
Jin, Z.1
Xiang, R.2
Qing, K.3
-
36
-
-
85019806116
-
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
-
Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322-3331.
-
(2017)
Blood
, vol.129
, Issue.25
, pp. 3322-3331
-
-
Gardner, R.A.1
Finney, O.2
Annesley, C.3
-
37
-
-
85062963594
-
Chimeric antigen receptor (CAR) T cells
-
Ascierto PA, Stroncek DF, Wang E, Switzerland: Springer
-
Lee DW, Wayne AS. Chimeric antigen receptor (CAR) T cells. In: Ascierto PA, Stroncek DF, Wang E, editors. Developments in T Cell Based Cancer Immunotherapies. Switzerland: Springer; 2015.
-
(2015)
Developments in T Cell Based Cancer Immunotherapies
-
-
Lee, D.W.1
Wayne, A.S.2
-
38
-
-
84869797922
-
IL-6 trans-signaling via the soluble IL-6 receptor: Importance for the pro-inflammatory activities of IL-6
-
Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237-1247.
-
(2012)
Int J Biol Sci
, vol.8
, Issue.9
, pp. 1237-1247
-
-
Rose-John, S.1
-
39
-
-
84977477922
-
Toxicities of chimeric antigen receptor T cells: Recognition and management
-
Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26): 3321-3330.
-
(2016)
Blood
, vol.127
, Issue.26
, pp. 3321-3330
-
-
Brudno, J.N.1
Kochenderfer, J.N.2
-
40
-
-
84897568616
-
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
-
Maude S, Barrett D, Teachey DT, Grupp SA. Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies. Cancer J. 2014;20(2):119-122.
-
(2014)
Cancer J
, vol.20
, Issue.2
, pp. 119-122
-
-
Maude, S.1
Barrett, D.2
Teachey, D.T.3
Grupp, S.A.4
-
41
-
-
85048256507
-
Sarilumab: A review in moderate to severe rheumatoid arthritis
-
Lamb YN, Deeks ED. Sarilumab: a review in moderate to severe rheumatoid arthritis. Drugs. 2018;78(9):929-940.
-
(2018)
Drugs
, vol.78
, Issue.9
, pp. 929-940
-
-
Lamb, Y.N.1
Deeks, E.D.2
-
42
-
-
84933510694
-
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
-
Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017-4023.
-
(2015)
Blood
, vol.125
, Issue.26
, pp. 4017-4023
-
-
Maude, S.L.1
Teachey, D.T.2
Porter, D.L.3
Grupp, S.A.4
-
43
-
-
85058453793
-
Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia
-
Epub, Sep 6
-
Mueller KT, Waldron ER, Grupp SA, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. Epub 2018 Sep 6.
-
(2018)
Clin Cancer Res
-
-
Mueller, K.T.1
Waldron, E.R.2
Grupp, S.A.3
-
44
-
-
85051407904
-
Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques
-
Nellan A, McCully CML, Cruz Garcia R, et al. Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. Blood. 2018;132(6):662-666.
-
(2018)
Blood
, vol.132
, Issue.6
, pp. 662-666
-
-
Nellan, A.1
McCully, C.2
Cruz Garcia, R.3
-
46
-
-
73949092345
-
Fontolizumab in moderate to severe Crohn’s disease: A phase 2, randomized, double-blind, placebocontrolled, multiple-dose study
-
Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, placebocontrolled, multiple-dose study. Inflamm Bowel Dis. 2010;16(2):233-242.
-
(2010)
Inflamm Bowel Dis
, vol.16
, Issue.2
, pp. 233-242
-
-
Reinisch, W.1
De Villiers, W.2
Bene, L.3
|